Depression and Anxiety Trial, Recruiting NCT06250842 Sponsor: The First Affiliated Hospital of Dalian Medical University Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT06250842
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been taking benzodiazepine medications (a type of sedative or anti-anxiety drug) continuously for 3 months or more, as well as people who have never taken benzodiazepines (to serve as a comparison group)
  • People who have completed at least 6 years of schooling
  • People who have not consumed alcohol, coffee, or any other mind-altering substances in the 24 hours before their assessment appointment

Who may not be able to join:

  • People who have a condition that has caused damage to the brain, such as a head injury, dementia, epilepsy, or a brain tumour
  • People who have a serious illness affecting the body, such as cancer
  • People who have had a stroke or other serious brain blood vessel event in the past 3 months
  • People who have a history of misusing substances other than benzodiazepines, such as alcohol or opioids
  • People who are unable to participate in brain scanning procedures (fNIRS and PET/MRI) or complete questionnaire-based assessments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hui min Zhang, The First Affiliated Hospital of Dalian Medical University

Phone: +86 18098876233

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The First Affiliated Hospital of Dalian Medical University
Registry
ClinicalTrials.gov
Start date
11 February 2024
Est. completion
20 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Brain hemodynamic activity with fNIRS; Longitudinal evolution of biomarkers measured from neuroimaging (including structural, functional, and multimodal MRI) and molecular neuroimaging (18F-FDG PET/MRI、DPA-714-PET/MRI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov